S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:SNCE

Science 37 (SNCE) Stock Price, News & Analysis

$5.71
0.00 (0.00%)
(As of 02/23/2024 ET)
Today's Range
$5.70
$5.74
50-Day Range
$4.10
$6.15
52-Week Range
$3.73
$12.96
Volume
40,329 shs
Average Volume
43,779 shs
Market Capitalization
$34.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Science 37 MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
250.3% Upside
$20.00 Price Target
Short Interest
Healthy
0.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.46 out of 5 stars

Medical Sector

726th out of 940 stocks

Commercial Physical Research Industry

10th out of 13 stocks


SNCE stock logo

About Science 37 Stock (NASDAQ:SNCE)

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

SNCE Stock Price History

SNCE Stock News Headlines

Science 37 (NASDAQ:SNCE) Trading Up 0.2%
eMed commences tender offer for Science 37
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE
A shocking leak has revealed tech giant Microsoft plans to add crypto support to future products. If the plans in these leaked documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, and MORE. The coupling of gaming and cryptocurrency could transform digital finance as we know it. We've gathered 27 experts to share their top picks and predictions for the 2024 crypto bull run.
Science 37 Initiates Cost-Cutting, Workforce Reduction Plan
Science 37 Holdings Inc SNCE
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE
A shocking leak has revealed tech giant Microsoft plans to add crypto support to future products. If the plans in these leaked documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, and MORE. The coupling of gaming and cryptocurrency could transform digital finance as we know it. We've gathered 27 experts to share their top picks and predictions for the 2024 crypto bull run.
Science 37 just downgraded at Craig-Hallum, here's why
Science 37 Shares Rise on Deal to Be Acquired
NDRA, LITM and SNCE among mid-day movers
Science 37 Receives Top Honors in Everest PEAK Matrix®
See More Headlines
Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/23/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:SNCE
Fax
N/A
Employees
460
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.00
High Stock Price Target
$20.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+249.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-50,990,000.00
Net Margins
-206.86%
Pretax Margin
-207.00%

Debt

Sales & Book Value

Annual Sales
$70.15 million
Book Value
$16.70 per share

Miscellaneous

Free Float
5,564,000
Market Cap
$34.15 million
Optionable
Not Optionable
Beta
0.53
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. David Coman (Age 54)
    CEO & Director
    Comp: $796.13k
  • Ms. Christine A. Pellizzari J.D. (Age 56)
    Chief Legal & Human Resources Officer and Secretary
    Comp: $521.58k
  • Ms. Darcy Forman (Age 48)
    Chief Delivery Officer
    Comp: $550.58k
  • Mr. Mike Zaranek (Age 53)
    Chief Financial Officer
  • Irena Lambridis
    VP and Head of Quality Assurance & Compliance
  • Ms. Margie Gimbel Kooman
    Vice President of Marketing & Communications
  • Mr. Drew Bustos
    Chief Strategy & Marketing Officer
  • Mr. Jonathan Cotliar M.D. (Age 52)
    Chief Medical Officer
    Comp: $486.6k
  • Mr. Michael Shipton (Age 52)
    Chief Commercial Officer
  • Mr. Tyler Van Horn
    VP of Corporate Strategy & Chief of Staff














SNCE Stock Analysis - Frequently Asked Questions

Should I buy or sell Science 37 stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNCE, but not buy additional shares or sell existing shares.
View SNCE analyst ratings
or view top-rated stocks.

What is Science 37's stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for Science 37's stock. Their SNCE share price targets range from $20.00 to $20.00. On average, they expect the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 250.3% from the stock's current price.
View analysts price targets for SNCE
or view top-rated stocks among Wall Street analysts.

How have SNCE shares performed in 2024?

Science 37's stock was trading at $5.34 on January 1st, 2024. Since then, SNCE stock has increased by 6.9% and is now trading at $5.71.
View the best growth stocks for 2024 here
.

Are investors shorting Science 37?

Science 37 saw a decline in short interest in January. As of January 31st, there was short interest totaling 30,600 shares, a decline of 65.2% from the January 15th total of 87,900 shares. Based on an average trading volume of 43,800 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.5% of the shares of the company are short sold.
View Science 37's Short Interest
.

When is Science 37's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our SNCE earnings forecast
.

When did Science 37's stock split?

Science 37 shares reverse split on the morning of Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Science 37's major shareholders?

Science 37's stock is owned by a variety of institutional and retail investors. Top institutional investors include Kent Lake Capital LLC (4.67%), Glynn Capital Management LLC (2.96%), Russell Investments Group Ltd. (2.84%), Vanguard Group Inc. (2.69%), Citadel Advisors LLC (1.13%) and Boston Partners (0.66%).
View institutional ownership trends
.

How do I buy shares of Science 37?

Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNCE) was last updated on 2/23/2024 by MarketBeat.com Staff